Business
BioMarin Announces CFO Succession
Brian R. Mueller, Chief Accounting Officer and 17-year company veteran, named acting CFO Dan Spiegelman steps down as CFO; will assist with transition until
About this update from Biomarin Pharmaceutical Inc.
[{"type":"text","content":"Brian R. Mueller, Chief Accounting Officer and 17-year company veteran, named acting CFO\n Dan Spiegelman steps down as CFO; will assist with transition until September 1, 2020\n\n\nSAN RAFAEL, Calif., Feb. 3, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced the transition of Executive Vice President and Chief Financial Officer Dan Spiegelman. Mr. Spiegelman will remain as an employee and senior advisor until September 1, 2020 to assist with the transition. After that, he plans to pursue other interests and spend more time with family. Brian R. Mueller, Senior Vice President, Finance and Chief Accounting Officer, has assumed the role of acting Chief Financial Officer. The Company is initiating an internal and external search for the role of Chief Financial Officer.\n\n \n \n\n \n\"On behalf of the entire Board and executive team, I would like to thank Dan for his important contributions and leadership during his tenure at the company. Over the last seven and a half years, he has played an invaluable role in supporting the company's growth,\" said Jean-Jaques Bienaimé, Chairman and Chief Executive Officer. \"I am confident that Brian in the acting CFO role will help us build on the strong foundation established and seamlessly execute on our business strategies. A veteran at BioMarin with 17 years of experience at the company, Brian has a deep knowledge of our business and throughout his career here has been essential in laying the ground work for BioMarin's continued long-term success.\" \nMr. Mueller has been with BioMarin since December 2002, during which time he has taken on roles of increasing responsibility. He has served as the Chief Accounting Officer since March 2011. Prior to that, Mr. Mueller served as Group Vice President, Corporate Controller. Mr. Mueller is a member of the board of directors and the Chairman of the Audit Committee of Anthera Pharmaceuticals, Inc. Before joining BioMarin, Mr. Mueller worked for KPMG as a senior manager in the firm's audit practice. Previously, he spent seven years with Arthur Andersen LLP in the firm's audit and business advisory services practice. \nBioMarin confirmed that it remains on track to report fourth quarter and full year 2019 financial results on February 26, 2020 and to file its annual report on Form 10-K shortly thereafter.\nAbout BioMarin...